Intellia Therapeutics, Inc. (NTLA): Cash & Equivalents
$155.46M
As of 2025-12-31
$106.13M
As of 2026-06-30
-33.3%
3-year compound annual growth
-0.6%
5-year compound annual growth
+7.4%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $155.46M | -17.8% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $189.18M | -16.6% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $226.75M | -56.7% | 2026-02-26, Balance as of period end |
| 2022-12-31 | $523.51M | +324.2% | 2025-02-27, Balance as of period end |
| 2021-12-31 | $123.41M | -22.9% | 2024-02-22, Balance as of period end |
| 2020-12-31 | $160.02M | +179.6% | 2023-02-23, Balance as of period end |
| 2019-12-31 | $57.23M | -2.8% | 2022-02-24, Balance as of period end |
| 2018-12-31 | $58.86M | -82.7% | 2021-02-26, Balance as of period end |
| 2017-12-31 | $340.68M | +24.8% | 2019-02-27, Balance as of period end |
| 2016-12-31 | $273.06M | +260.2% | 2019-02-27, Balance as of period end |
| 2015-12-31 | $75.82M | +670.1% | 2018-03-14, Balance as of period end |
| 2014-12-31 | $9.85M | n/a | 2017-03-14, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Intellia Therapeutics, Inc. (NTLA) | 2025-12-31 | $155.46M | -17.8% |
| Alpha Teknova, Inc. (TKNO) | 2025-12-31 | $5.91M | +59.4% |
| Immucell Corp (ICCC) | 2025-12-31 | $3.81M | +1.3% |
| Aspira Women's Health Inc. (AWHL) | 2025-12-31 | $1.75M | -0.8% |
| Anbio Biotechnology (NNNN) | 2025-12-31 | $7.77M | -34.0% |
| Myriad Genetics Inc (MYGN) | 2025-12-31 | $149.60M | +46.1% |
| Neogen Corp (NEOG) | 2026-05-31 | $185.50M | +43.8% |
| Biomerica Inc (BMRA) | 2026-05-31 | $1.31M | -45.5% |
| Insight Molecular Diagnostics Inc. (IMDX) | 2025-12-31 | $11.58M | +34.1% |
Compare NTLA, TKNO, ICCC, AWHL side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗